Use of the Incisionless Operating Platform as a Primary Treatment for Obesity vs. Diet-Exercise Alone (MILEPOST)

This is an interventional treatment trial for Obesity focused on measuring g-Cath EZ Suture Anchor Delivery Catheter, Weight Loss Intervention Read More

Inclusion Criteria:

• Age 20-60 years
• Body Mass Index [BMI] of >30 and <40 with or without a co-morbid condition
• Subject has failed more conservative weight reduction alternatives such as supervised diet, exercise or behavior modification programs in the last year
• No significant weight change (+/- 5% of total body weight) in last 6 months
• American Society Anesthesiologists-Physical Status score ≤ 2 (Appendix III),
• Subject agrees not to have any additional weight loss interventional procedures or liposuction for at least 30 months following study enrollment,
• Has not taken any prescription or over the counter weight loss medications for at least 6 months,
• Signed informed consent.
• Subject is willing to cooperate with post-operative dietary recommendations and assessment tests,

Exclusion Criteria:

• History of (or intraoperative evidence of) bariatric, gastric or esophageal surgery
• Esophageal stricture or other anatomy and/or condition that could preclude passage of endolumenal instruments
• Severe gastroesophageal reflux disease (GERD), defined as symptoms that cause subject severe discomfort, compromise performance of daily activities, and/or condition is not entirely controlled with prescription drug therapy
• Known hiatal hernia >3 centimeters by history or as determined by Upper Gastrointestinal exam or endoscopy
• Pancreatic insufficiency/disease
• Active peptic ulcer
• Pregnancy or plans of pregnancy in the next 12 months
• Present Corticosteroid Use
• History of inflammatory disease of Gastrointestinal [GI] tract; Coagulation disorders; hepatic insufficiency or cirrhosis
• History or present use of insulin or insulin derivatives for treatment of diabetes
• Type II Diabetes Mellitus [DM] (as defined by Glycosylated Hemoglobin [HgbA1c] >6.5) for greater than 2 years at the time of enrollment
• Uncontrolled Type II DM (HgbA1c > 7.0 at screening)
• Quit smoking within last 6 months at time of enrollment or plans to quit smoking in the next year
• Immunosuppression
• Portal hypertension and/or varices
• Active gastric ulcer disease
• Gastric outlet obstruction or stenosis
• Beck Depression Inventory (Short) Score ≥12 (see Appendix IV);
• Subject has a history of drug or alcohol abuse or actively abusing either as defined by Cage and DAST [drug use] questionnaires or positive Urinalysis [UA] drug screen
• Severe disturbances in eating behavior (i.e. binge eating)
• Known presence of a significant depression, psychosis, or other mood or eating disorder
• Actively treated depression (except for stable treated depression for >1year and normal [Beck Depression Inventory [BDI] and psych exam)
• Present or past history of psychosis or other mood or eating disorder
• Non-ambulatory or has significant impairment of mobility
• Known hormonal or genetic cause for obesity with the exception of treated hypothyroidism.
• Participating in another clinical study
• Is a first degree relative of investigator, or support staff involved in the study.
• Employed by investigator or institution involved in the study
• Subject is not able to provide written informed consent